angiotensin II receptor blocker


Also found in: Dictionary, Acronyms.

angiotensin II receptor blocker

a drug that binds with angiotensin receptors, preventing endogenous angiotensin II from acting on them and thus reducing the vasoconstriction and sodium retention usually induced by that agonist.

The renin-angiotensin-aldosterone system regulates blood pressure and electrolyte balance. Angiotensin II is a potent vasoconstrictor and neurotransmitter that raises peripheral vascular resistance, induces aldosterone secretion by the adrenal cortices and hence sodium retention, and promotes endothelial dysfunction and the growth and proliferation of vascular smooth muscle. Because angiotensin II plays a pivotal role in the pathogenesis of essential hypertension, congestive heart failure, and diabetic nephropathy, drugs that block its production or action are useful in these and other disorders. Angiotensin receptor blockers (ARBs) in current use are nonpeptides that selectively inhibit the AT1 receptor. In essential hypertension, ARBs have the potential for achieving broader control than angiotensin-converting enzyme (ACE) inhibitors because angiotensin II is generated in tissues, particularly diseased tissues, by enzymes besides ACE. ARBs have been shown to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (LVH), to reverse LVH in such patients, and slow the progression of diabetic nephropathy in those with Type 2 diabetes mellitus and hypertension. ARBs are safe and well tolerated. Unlike ACE inhibitors, they do not inhibit the degradation of bradykinin and hence do not cause cough as a side-effect. Currently, they are approved by the U.S. Food and Drug Administration only for the treatment of hypertension and, in those intolerant of ACE inhibitors, of heart failure. The generic names of angiotensin II receptor blockers end in -sartan, which is derived from the phrase selective angiotensin receptor antagonist.

angiotensin II receptor blocker

n. Abbr. ARB
Any of a class of drugs that reduce peripheral vascular resistance by inhibiting the action of the vasoconstrictor angiotensin II, used in the treatment of hypertension, heart failure, and other cardiovascular disorders. Also called angiotensin receptor blocker, angiotensin II receptor antagonist.

an·gi·o·ten·sin II re·cep·tor block·er

(ARB) (an'jē-ō-ten'sin rĕ-sep'tŏr blok'ĕr)
A drug that binds with angiotensin receptors, preventing endogenous angiotensin II from acting on them and thus reducing the vasoconstriction and sodium retention usually induced by that agonist; used to treat hypertension.
References in periodicals archive ?
Pharmacokinetic parameters of angiotensin II receptor blockers * Active Bioavail Food Drug metab (%) effect Losartan Yes 33 No Valsartan No 25 Yes Irbesartan No 70 No Candesartan Yes 42 No Telmisartan No 43 No Eprosartan No 15 No Olmesartan Yes 26 No Half-life (hrs) Drug Drug Metab Losartan 2 6-9 Valsartan 9 -- Irbesartan 11-15 -- Candesartan 3.
Hypertension and its impact on cardiovascular health have long been studied; the goal of this particular study was to determine whether a fixed-dose combination of a well-established yet underutilized diuretic paired with a new angiotensin II receptor blocker would provide an effective option to help control hypertension," said study co-author Michael Weber, M.
CHICAGO -- Spironolactone and statins added to ACE inhibitors and angiotensin II receptor blockers further reduces proteinuria and the rate of chronic kidney disease progression, a study has found.
Developed by Takeda, EDARBI is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension to lower blood pressure in adults.
The fixed-dose combination of azilsartan medoxomil plus chlorthalidone contains two medications, azilsartan medoxomil, an angiotensin II receptor blocker, and chlorthalidone, a long-acting thiazide-like diuretic used in the treatment of hypertension.
Discovered by Takeda, azilsartan medoxomil, also known as TAK-491, is an angiotensin II receptor blocker currently in development for the treatment of hypertension, or high blood pressure, either used alone or in combination with other classes of antihypertensive agents.
It is testing the hypothesis that the angiotensin II receptor blocker irbesartan is superior to placebo when added to other antihypertensive agents in patients with atrial fibrillation, noted Dr.
Results from Val-MARC (Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hsCRP) also showed that valsartan's effect on C-reactive protein (CRP) was independent of blood pressure reduction, suggesting that a pleiotropic, anti-inflammatory effect by this angiotensin II receptor blocker (ARB) might have produced the result.
today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.
submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension.
All patients with diabetes and hypertension should receive an ACE inhibitor or an angiotensin II receptor blocker as one component of their therapy.
In high-risk patients who cannot tolerate an angiotensin-converting enzyme (ACE) inhibitor, the TRANSCEND trial was designed to investigate potential cardiovascular risk reduction benefits using the second-generation angiotensin II receptor blocker (ARB) telmisartan.

Full browser ?